Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Rocket Pharmaceuticals, Inc. - Common Stock
(NQ:
RCKT
)
2.900
+0.020 (+0.69%)
Streaming Delayed Price
Updated: 1:00 PM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Rocket Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
May 31, 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via
Benzinga
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
May 28, 2025
Rocket Pharmaceuticals faces trial delays, multiple downgrades, and reduced success expectations following RP-A501 safety concerns.
Via
Benzinga
Booz Allen, FreshPet, Rocket Pharma Downgraded, While Vail Resorts And FICO Get An Upgrade – Top Wall Street Analyst Calls Today
May 28, 2025
State Street received an upgrade from Truist, raising the stock to ‘Buy’ from ‘Hold’ and increasing its price target to $112 from $85.
Via
Stocktwits
Topics
ETFs
Stocks
Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday
May 28, 2025
Via
Benzinga
These Analysts Slash Their Forecasts On Rocket Pharmaceuticals
May 28, 2025
Via
Benzinga
Top 3 Health Care Stocks That Could Blast Off This Month
January 06, 2025
Via
Benzinga
This Informatica Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday
May 28, 2025
Via
Benzinga
Patient Death In Rocket Pharma Trial Triggers Downgrades, But Retail Traders Bet Big On Strong Recovery
May 28, 2025
Message volume on Stocktwits spiked to ‘extremely high’ levels, and the ticker added 20% more watchers.
Via
Stocktwits
Topics
Death
Here are the top movers in Tuesday's session.
May 27, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 27, 2025
Via
Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
May 27, 2025
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via
Chartmill
Dow Surges Over 600 Points; US Durable Goods Orders Fall in April
May 27, 2025
Via
Benzinga
Topics
Stocks
Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold
May 27, 2025
Rocket Pharmaceuticals halted its Danon disease gene therapy trial after a patient death, with the FDA placing the study on clinical hold for review.
Via
Benzinga
There are notable gap-ups and gap-downs in today's session.
May 27, 2025
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings
May 27, 2025
Via
Benzinga
Rocket Pharmaceuticals Stock Drops Pre-Market After FDA Pauses Gene Therapy Trial Over Patient Death: Retail Turns Bullish
May 27, 2025
Rocket Pharmaceuticals said that it is working with the FDA to ensure safety of all study patients and resume the trial “as expeditiously as possible."
Via
Stocktwits
Stay updated with the stocks that are on the move in today's pre-market session.
May 27, 2025
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 27, 2025
Via
Benzinga
Rocket Pharma's Gene Therapy Shows Promise in ACM Patients, Says Analyst
May 16, 2025
Chardan's Geulah Livshits raises target price for RCKT to $46 and maintains Buy rating after promising data on gene therapy for heart disease.
Via
Benzinga
Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday
May 16, 2025
Via
Benzinga
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
April 21, 2025
Via
Benzinga
3 Stocks Insiders Are Buying Rapidly Amid Market Volatility
April 17, 2025
Despite market volatility, these stocks are seeing strong buys by insiders.
Via
Talk Markets
Topics
Stocks / Equities
Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Monday
April 15, 2025
Via
Benzinga
3 Small-Cap Stocks That Are Ready to Rocket Higher
November 27, 2024
With lower interest rates and lower corporate taxes more likely, it's a good time to consider three small-cap stocks that present a buying opportunity
Via
MarketBeat
Topics
Government
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst
November 19, 2024
Rocket Pharmaceuticals reveals RP-A501 Phase 1 data for Danon disease, showing durable efficacy, reduced cardiac biomarkers, and improved heart health.
Via
Benzinga
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
August 26, 2024
Via
Benzinga
RCKT Stock Earnings: Rocket Pharmaceuticals Misses EPS for Q2 2024
August 05, 2024
RCKT stock results show that Rocket Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides
June 28, 2024
Rocket Pharmaceuticals shares fell after the FDA issued a Complete Response Letter for Kresladi, a gene therapy for severe leukocyte adhesion deficiency-I. The FDA requested additional CMC...
Via
Benzinga
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
June 28, 2024
Via
Benzinga
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains
June 14, 2024
These biotech stocks, lacking in profitability but seeding huge potential, should be on your watchlist.
Via
Talk Markets
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.